Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)

03.11.2022 - Media Release Copenhagen, Denmark, November 3, 2022 Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody-CD3xCD20) in a variety of treatment settings and hematologic ...

Related Keywords

Netherlands ,Cairo ,Al Qahirah ,Egypt ,Japan ,Tokyo ,United States ,Denmark ,Copenhagen ,Køavn ,New Jersey ,Oostindie ,Groningen ,American ,David Freundel ,Kalvebod Brygge ,Epcoritamab Monotherapy ,Judith Klimovsky ,Andrew Carlsen ,Product Communications ,Macrophage Propertiesj Immunol ,Twitter ,Exchange Commission ,American Society Of Hematology ,Health Care Resource Utilization ,Development Of Novel Anti ,Company Announcement ,Executive Vice President ,Chief Development Officer ,American Society ,Yearly Results ,Refractory Diffuse Largeb Cell Lymphoma Eligible ,Autologous Stem Cell Transplant ,Updated Phase ,Refractory Follicular Lymphoma ,First Line Treatment ,Follicular Lymphoma ,Initial Results ,Novel Subgroup Analyses ,Largeb Cell ,Lymphoma Symptoms ,Health Related Quality ,Refractory Largeb Cell Lymphoma Treated ,Subcutaneous Epcoritamab Dose Expansion ,Patients With Relapsed ,Refractory Largeb Cell ,Non Hodgkin Lymphomas ,Newly Diagnosed Patients ,Refractory Aggressive Matureb Cell ,Rituximab Combination ,Preclinical Models ,Subcutaneous Epcoritamab ,Combination With Rituximab ,Epcoritamab Among Patients With Relapsed ,Evaluate Safety ,Outpatient Setting Among Patients With Relapsed ,Refractory Diffuse Grade ,Novel Combinations ,Anti Neoplastic Agents ,Non Hodgkin Lymphoma ,Dose Escalation Results From ,First In Human Phase ,With Relapsed ,Multiple Myeloma ,World Outcomes ,Refractory Diffuse Largeb Cell Lymphoma Treated ,Patients With Follicular Lymphoma Receiving ,Real World Evaluation ,Care Resource Utilization ,Patients With Largeb Cell Lymphoma ,Investor Relations ,Vice President ,Annual Report ,Media Releasenor ,Y Shaped Genmab ,Clinically Utilized ,Directed Antibodies ,Macrophage Properties ,Novel Anti Cd ,Cell Surface ,Cancer Sci ,